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Abstract
In 2010, global immunization partners posed the question, “Do new vaccine introductions (NVIs) 
have positive or negative impacts on immunization and health systems of countries?” An Ad-hoc 
Working Group was formed for WHO’s Strategic Advisory Group of Experts on immunization 
(SAGE) to examine this question through five approaches: a published literature review, a grey 
literature review, in-depth interviews with regional and country immunization staff, in-depth 
studies of recent NVIs in 3 countries, and a statistical analysis of the impact of NVI on DTP3 
coverage in 176 countries. The WHO Health System Framework of building blocks was used to 
organize the analysis of these data to assess potential areas of impact of NVI on health systems. In 
April 2012, the Ad-hoc Working Group presented its findings to SAGE. While reductions in 
disease burden and improvements in disease and adverse events surveillance, training, cold chain 
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and logistics capacity and injection safety were commonly documented as beneficial impacts, 
opportunities for strengthening the broader health system were consistently missed during NVI. 
Weaknesses in planning for human and financial resource needs were highlighted as a concern. 
Where positive impacts on health systems following NVI occurred, these were often in areas 
where detailed technical guidance or tools and adequate financing were available. SAGE 
supported the Ad-hoc Working Group’s conclusion that future NVI should explicitly plan to 
optimize and document the impact of NVI on broader health systems. Furthermore, opportunities 
for improving integration of delivery of immunization services, commodities, and messages with 
other parts of the health system should be actively sought with the recognition that integration is a 
bidirectional process. To avoid the gaps in planning for NVI that can compromise existing 
immunization and health systems, donors and partners should provide sufficient and timely 
support to facilitate country planning. Areas for future research were also identified. Finally, to 
support countries in using NVI as an opportunity to strengthen immunization and health systems, 
the WHO guidance for countries on new vaccine introduction is being updated to reflect ways this 
might be accomplished.
Keywords
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1. Introduction
The introduction of new vaccines into national immunization programmes expands 
opportunities to prevent substantial morbidity and mortality from an increasing number of 
diseases. The Expanded Programme on Immunization (EPI) was originally established by 
the World Health Assembly in 1974 to target “some or all of the following diseases: 
diphtheria, pertussis, tetanus, measles, poliomyelitis, tuberculosis, smallpox and others, 
where applicable, according to the epidemiological situation in their respective countries” 
[1]. Following the establishment of EPI, the six EPI vaccines in wide use remained fairly 
stable for 20–30 years. However, during the past decade, scientific advancements and 
renewed global commitment to immunization have made an array of additional vaccines 
available to countries, including to low-income countries. As a consequence, new vaccine 
introductions (NVIs) have dramatically accelerated.
Successful introductions of new vaccines depend on well-functioning routine immunization 
and health systems [2]. Because NVIs require these systems to expand their scope, they can 
also pose challenges to those systems. Weaknesses in NVIs identified during post-
introduction evaluations are commonly found to be related to underlying gaps in 
immunization or health systems, attesting to this correlation between the robustness of a 
country’s immunization and health systems and the success of a NVI. Concern has been 
expressed that NVIs could overburden health systems in low- and middle-income countries. 
On the other hand, introduction of new vaccines could exert a positive effect and offer 
important opportunities to strengthen health systems.
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In June 2009, the WHO Maximizing Positive Synergies Collaborative Group reported on its 
assessment of the interactions between global health initiatives (GHIs) and country health 
systems [3]. Recognizing that both positive and negative impacts on health systems have 
been attributed to GHIs for polio, HIV/AIDS, malaria, and other major initiatives, global 
immunization partners posed the question, “Do NVIs have positive or negative impacts on 
immunization and health systems of countries?”.
With several groups interested in this question – including the World Health Organization 
(WHO), the United States Centers for Disease Control and Prevention (CDC), PATH, the 
London School of Hygiene and Tropical Medicine (LSHTM), the Maternal and Child Health 
Integrated Program (MCHIP), the Bill & Melinda Gates Foundation (BMGF), the World 
Bank, UNICEF, Johns Hopkins Bloomberg School of Public Health, and the GAVI Alliance 
– there developed an interest in coordinating and collaborating on the various streams of 
investigation. Early in 2010, an Ad-hoc Working Group, including members from each of 
the interested groups, was created to examine this issue for WHO’s Strategic Advisory 
Group of Experts on immunization (SAGE) [4]. The Ad-hoc Working Group embarked on a 
multi-component examination of the impact of NVIs on immunization and health systems, 
followed by a joint analysis of the findings, identification of knowledge gaps, and initiation 
of next steps to translate the findings into practical considerations for programme 
implementation. In April 2012, the Ad-hoc Working Group presented its findings to SAGE. 
This paper reviews the Ad-hoc Working Group’s body of completed work, the implications 
of findings, and next steps.
2. Methods
NVI was defined as the introduction of any vaccine beyond the original six EPI vaccines 
against diphtheria, pertussis, tetanus, measles, poliomyelitis, and tuberculosis. The WHO 
Health System Framework building blocks [5] was used to organize the analysis of potential 
areas of impact of NVI on immunization and health systems (Fig. 1). Health systems may be 
characterized by a set of activities encompassing: service delivery; health workforce; 
information; medical products, vaccines and technologies; financing and sustainability; and 
leadership and governance.
The range of methods used to investigate impacts included: (1) a review of published 
literature; (2) a review of grey literature; (3) in-depth case studies in three countries; (4) 
interviews with key informants from countries and WHO Regional Offices; and (5) a 
multivariable analysis examining impact of NVI on coverage for 3rd dose of diphtheria–
tetanus–pertussis vaccine (DTP3). Although five different methods were used, consistent 
application of the WHO Health System Framework building blocks to organize data allowed 
for coherent analysis. Table 1 provides an overview of the data sources and their 
characteristics.
2.1. Published literature review
Seven publication databases (Medline, Embase, Nursing Update, West African Journal of 
Nursing, CINAHL, Web of Science and Global Health) were searched for the published 
literature review [6], using 104 terms encompassing vaccines, immunization systems, and 
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health systems themes. The search, completed on September 29, 2010 and not limited to a 
beginning year, yielded 24,768 articles. After a standardized review process in which titles 
and abstracts were screened using set inclusion and exclusion criteria, 130 relevant articles 
were selected for inclusion in the analysis. A standard abstraction form was developed to 
systematically abstract information on the study setting, methodology, relevance and impact 
on immunization and health system. Most of the articles analyzed in the review pertained to 
experiences in high-income countries.
2.2. Grey literature review
A systematic search of the grey literature [7] included documents that were not peer-
reviewed or published commercially, and were written between January 2000 and October 
2010. Popline, PubMED, Cochrane Library, ELDIS, System for Information on Grey 
Literature in Europe, CAB Abstracts, and WHO regional office databases were searched 
using a combination of free text and MESH terms. In addition, websites of agencies working 
on immunization and NVI were searched, and additional documents were identified through 
networking. From among a total of approximately 300 documents, 61 were identified that 
contained information on the impact of NVI on immunization programmes and, in a few 
cases, on the broader health system. Most of the 61 documents were Post-Introduction 
Evaluations (PIEs), PIE summaries, meeting reports and presentations, and consultant 
reports. These documents focused on low- and middle-income countries.
2.3. In-depth study of three countries
Three low- and middle-income case countries were selected to reflect a variety of vaccines 
and health systems contexts. Field work was conducted in Guatemala to evaluate a February 
2010 introduction of rotavirus vaccine, in Kenya to examine a February 2011 introduction of 
10 valent pneumococcal conjugate vaccine (PCV10), and in Mali to assess the introduction 
of Meningococcal A vaccine through campaigns conducted between September 2010 and 
November 2011 [8]. Semi-structured interviews were conducted with key informants to 
assess the impact of NVIs on the health systems of the countries. One hundred-sixteen 
interviews were conducted with national, regional and district staff. In addition, 
questionnaires were completed with staff from 87 facilities in selected districts. Interviewees 
were identified through snowball sampling and field locations were selected to reflect 
various levels of vaccination coverage, as a proxy for health system strength. In each 
country, selected routine data were collected at health facility level, including number 
vaccinated and number receiving antenatal care services before and after the new vaccine 
was introduced.
2.4. Interviews with country and regional informants
During the annual Global New and Under-utilized Vaccine Implementation meeting in 
Montreux, Switzerland in June 2011, semi-structured interviews were conducted with nine 
senior national immunization and health officials and seven WHO regional office staff to 
gain their perspectives on the impact of recent NVIs on immunization and health systems 
[9]. Informants were also asked about their views on possible tools to develop for countries 
to provide guidance on minimizing potential negative effects and maximizing positive 
impacts on systems when introducing a new vaccine.
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2.5. Analysis of impact on DTP3 coverage
Multivariable, cross-national, longitudinal models were developed to evaluate the effect of 
NVI on DTP3 coverage in 176 countries during 1999–2009 [10]. DTP3 coverage data from 
the WHO-UNICEF Coverage Estimates [11] were regressed on variables representing the 
introduction of new vaccines to determine whether NVI significantly contributed to changes 
in DTP3 coverage in the birth cohort born in the year of NVI. The models controlled for 
underlying determinants of DTP3 coverage, including national income, access to health 
services and population health.
3. Results
Findings based on the information available from reviewing the five data sources are 
described below by WHO health system building block. Available data on impact of NVI on 
immunization and health systems from the data sources were qualitative, rather than 
quantitative. It was not possible to establish pre-set indicators for assessment of impact for 
each building block; whatever findings could be gleaned from the five data sources on any 
aspect of impact for each building block were extracted. Further details and findings for 
each data source may be found by reviewing documents located under “Session: Impact of 
introduction of new vaccines on the strengthening of immunization and health systems” and 
particularly “Summary of main themes and findings from review of 5 data sources by WHO 
health system building blocks” [12], located at http://www.who.int/immunization/sage/
meetings/2012/april/presentationsbackgrounddocs/en/index.html.
3.1. Service delivery
NVIs appeared to have mixed effects on immunization programmes. Although senior 
immunization respondents commonly described short-term improvement in coverage for 
routine vaccines, particularly when introducing new vaccines that targeted highly visible 
diseases, the analysis of impact of NVI on DTP3 coverage using the multivariable, 
longitudinal model found no association between the introduction of a new vaccine, either 
positive or negative, when controlling for other possible determinants of coverage. Short-
term negative effects on coverage for routine vaccines as well as for other health services 
were observed during vaccine campaigns conducted for NVI examined through the in-depth 
country study. Generally, new vaccines increased community acceptance of immunization 
programme activities and were viewed positively by health workers; the occasional 
exceptions to this were related to activity by anti-vaccination movements. There was a 
generally reported positive impact because of increased use of safe injection equipment and 
improvements in safe immunization practices. It was not possible to ascertain the impact of 
NVI on overall non-immunization health service delivery.
3.2. Health workforce
NVIs appeared to have mixed effects on the health work-force who conducted immunization 
activities. There were positive impacts on health worker immunization skills associated with 
the training and the short-term enhanced supervision that accompanied NVI. In a number of 
countries, the ability to offer clients an additional effective health intervention increased 
health worker motivation. There was at least a short-term increase in staff workload during 
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vaccine introductions. However, countries did not expand their workforces except briefly in 
the case of specific delivery strategies such as delivery through vaccination campaigns or 
schools. It was not possible to ascertain impact of NVI on non-immunization activities of the 
health workforce.
3.3. Information
NVI appeared to have mostly positive effects on information related to immunization 
systems. Disease surveillance systems at health facility and laboratory levels improved in 
several countries with enhanced surveillance of diseases prevented by new vaccines. 
Improved awareness and reporting of Adverse Events Following Immunization (AEFIs) 
occurred as a result of NVIs in a number of countries. Improvements in surveillance of 
vaccine preventable diseases led to some improvements in surveillance for other diseases 
but there were no data on impact of NVI on other health system information systems.
3.4. Supply management (medical products, vaccines, and technologies)
NVI had mixed effects on supply management for immunization systems. Assessment and 
expansion of cold chain infrastructure often occurred at the national or central level but cold 
chain infrastructure often remained inadequate at the local or peripheral levels. Even some 
middle-income countries experienced significant short-term stress on cold storage and 
transportation capacity for vaccines and other health commodities with NVI. Introductions 
of combination vaccines placed less stress on immunization systems than introductions of 
single antigen vaccines. The supply and use of safe injection equipment (auto-disable 
syringes and safety boxes) was noted to have greatly increased due to NVIs. However, 
existing weaknesses in vaccine forecasting and stock management were sometimes 
amplified with NVIs. There was generally no significant improvement in immunization 
waste disposal, despite increased needs. For health systems generally, there was some 
limited evidence of positive impact on supply management. In several countries, use of auto-
disable syringes and safety boxes for newly introduced vaccines led to their use for other 
health services. In addition, for a few countries, planning of cold chain expansion for 
vaccines took cold chain expansion for other medical products into consideration.
3.5. Financing and sustainability
NVIs appeared to have mixed effects on financing and sustainability of immunization 
programmes. There were substantial increases in programme costs as new vaccines were 
more expensive than traditional vaccines and collateral expenses related to NVIs were often 
not adequately anticipated or budgeted. NVIs led to diversification of financing mechanisms 
and funding sources, including greater government co-financing in some countries and the 
development of innovative global financing mechanisms. Vaccine introductions also raised 
concerns of countries being overly dependent on donors and of uncertainty about long-term 
sustainability of financing for the new vaccines. However, in the short term, most countries 
successfully managed to mobilize vaccine co-financing and to sustain funding for safe 
injection equipment. There was some evidence of reduced expenditures for the health 
system since NVIs contributed to a reduced need for outpatient visits and hospitalizations, 
with associated reductions in the costs of treating diseases and of responding to disease 
outbreaks.
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3.6. Leadership and governance
NVIs appeared to have positive effects on leadership and governance of immunization 
programmes. Prompted by activities related to NVI, national immunization technical 
advisory groups were established or strengthened in a number of countries, and there was 
increased recognition of the importance of national regulatory authorities. There was some 
evidence of positive impact on leadership and governance for the overall health system since 
NVIs led to improved coordination between ministries of health and other government 
ministries, especially with expansion of vaccination to new target age groups such as school-
age children and adults.
4. Discussion
Characterization of the impact of a NVI arguably varies depending not only on the strength 
of the immunization programme and the health system, but also depending on the vaccine 
characteristics, the target population, and the delivery mode. Findings from an assessment of 
impact on an immunization programme or health system can also vary depending on the 
effect being measured and the timing of the assessment (e.g., 6 weeks, 6 months, 12 months 
or 2 years after NVI). For these reasons, it was challenging to compare and contrast findings 
from a multitude of introductions with an array of different vaccines, populations, delivery 
strategies, timelines, immunization programmes, health systems, and country contexts.
The WHO Health System Framework of building blocks provided a useful structure for 
comparing data across this array of studies (for details, please see Annex, pages 8–14 [12]). 
Despite different methodological approaches, the major findings and themes were 
remarkably consistent across the 5 evaluations, suggesting robustness of the findings.
NVI was associated with positive health system effects. New vaccines resulted in reduced 
disease incidence that contributed to decline in use of curative services. NVIs brought new 
technologies such as auto-disable syringes and combination vaccines, enhancements to cold 
chain, emphasis on training and education of health workers, and increased social 
mobilization. Technical capacity was increased through strengthened national immunization 
technical advisory groups, more robust systems for disease surveillance, improvements in 
injection safety, and more emphasis on AEFI monitoring. Furthermore, communities and 
health workers generally welcomed the introduction of new vaccines, particularly for 
diseases with well-recognized and substantial health burdens.
Negative effects associated with NVI appeared to arise when planning was inadequate. For 
example, at the time of NVI, the peripheral cold chain was not always sufficient and the 
workload for health workers was sometimes quite heavy. Diversion of efforts toward NVI 
and away from other aspects of the routine immunization programme was highlighted as a 
concern. Collateral operational costs of NVI were not always adequately considered or 
funded and social mobilization and communication were not always sufficiently 
implemented to adequately educate communities. Different vaccine delivery strategies were 
noted to have collateral effects – for example, although vaccination campaigns can be highly 
effective in quickly vaccinating large populations, they could potentially harm routine 
vaccine coverage and reduce short-term availability of other primary health services. 
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However, this is a characteristic of the delivery strategy rather than whether the vaccine is 
new to the country and thus can also be seen with other public health service delivery 
campaigns.
In general, positive effects that occurred following NVI were often in areas for which 
detailed technical guidance or tools and adequate financing were available (e.g., cold chain, 
training, surveillance). Importantly, NVI did not commonly occur in tandem with greater 
integration, coordination, or synergies with other health services. Thus, opportunities for 
strengthening the broader health system were often missed during NVIs. There was minimal 
evidence that NVI led to deliberate strategies to use the introduction to strengthen routine 
immunization or other health services. This finding is consistent with other findings on the 
evaluation of interactions between disease control programmes and wider health systems 
[13,14].
To tackle the disconnect between NVI and health system strengthening, future efforts will 
need to address the specific knowledge gaps identified by this analysis of 5 data sources 
(Box 1) so that progress can be made to better understand the impact of NVIs on 
immunization programmes and health systems and how to make that impact beneficial. 
While this body of work attempted to examine the impact on immunization and health 
systems from a variety of perspectives, the published and grey literature reviews highlighted 
the lack of research designed to evaluate this essential question.
Box 1
Knowledge gaps deserving further evaluation
Areas for future evaluation to better understand impact of vaccine introduction on health 
systems
• Health system: How can the success of a vaccine introduction on the 
immunization and health systems be appropriately measured? What are the 
health system determinants of successful vaccine introduction? What aspects of 
vaccine introduction are key determinants for negative or positive impacts on 
health systems? How can the success of a vaccine introduction be appropriately 
measured from a broad health system perspective?
• Integrated service delivery: Which health interventions are most appropriate for 
integration with vaccine delivery? Under what circumstances? What additional 
resources or conditions are needed? How can planning be improved to enhance 
integration?
• Costs and financing: What are the actual costs of new vaccine introduction, 
including collateral costs? Is there re-direction of resources from other health 
programmes to finance vaccine introductions?
• Equity: What can be done to improve equity of access and health benefits when 
a vaccine is being introduced?
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Another way to address the absence of an adequate link between NVI and health systems 
strengthening is by systematically considering and developing plans to optimize the impact 
of vaccine introduction on broader health systems, and by monitoring and evaluating those 
efforts. As an initial step in this direction, the Ad-hoc Working Group translated the findings 
from this data analysis into more practical information for countries by developing 
Principles for Adding a Vaccine to a National Immunization Programme. In January 2012, 
the Principles were shared for review, comments, and endorsement by global immunization 
partners. The Principles were further finalized and endorsed at the April 2012 SAGE 
meeting (Box 2) [15].
Box 2
Principles for adding a vaccine to a national immunization programme 
while strengthening the immunization and health systems
Optimal new vaccine introduction that strengthens health systems benefits from:
1. A strong, country-led, evidence-based decision-making, planning, and 
prioritization process that is accountable and coordinated with other components 
of the health system.
2. A well-performing or improving and responsive immunization programme.
3. Seizing the opportunity to achieve:
• A well-trained and motivated workforce
• Quality education and communication about the new vaccine for the 
health workforce and community
• Functional cold storage, logistics and vaccine management systems
• Safe immunization practices and monitoring of adverse events
• High-quality monitoring and evaluation, including disease surveillance 
and immunization coverage monitoring
• Resource, performance, and management accountability.
4. Maximizing opportunities to deliver vaccines as integral components of 
comprehensive health promotion and disease prevention and control efforts so 
that vaccines are delivered as part of a package of effective, feasible, and 
affordable interventions based on national contexts.
5. Sufficient allocation of human and financial resources to introduce the new 
vaccine and sustain its use without adversely affecting other programmes and 
services.
6. A safe and efficacious vaccine that is appropriate for local use and is available 
with an uninterrupted, sufficient supply.
To further support countries to explicitly consider and plan to optimize the impact of NVI on 
immunization programmes and the broader health systems, the 2005 WHO Vaccine 
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Introduction Guidelines [16] are being updated to assist decision-makers, country 
immunization programme managers, and global partners with identifying and taking 
opportunities to strengthen the health system throughout the process of NVI, from decision-
making through planning, implementation, and evaluation. The forthcoming WHO 
guidance, entitled “Principles and considerations for adding a vaccine into a national 
immunization programme,” outlines considerations to be addressed for strengthening the 
health system that are intended to be flexibly applied to suit local contexts; these 
considerations are not intended as requirements or obstacles to NVI.
Viewing health service delivery in a holistic and integrated manner rather than as 
independent, disparate programmes is recognized as necessary in order to achieve 
efficiencies and avoid fragmentation. Opportunities for improving integration of delivery of 
services, commodities, and messages with other parts of the health system should be actively 
sought with the recognition that integration is a bi-directional process, so success will take 
time, effort, and mutual collaboration.
For the donor and partner community, this analysis highlights the need to avoid the gaps in 
planning and resourcing for NVI that can compromise or burden existing immunization and 
health systems. Where financial and technical resources are being offered, donors and 
partners should provide such support in a timely and sufficient manner to facilitate country 
planning and to support evaluation of impact of NVI on health systems.
All six of the strategic objectives of the Global Vaccine Action Plan (GVAP), endorsed by 
the World Health Assembly in May 2012 [2], are essential for NVIs and for continuous 
improvement of immunization and health systems. In particular, the Ad-hoc Working 
Group’s analysis underscores the importance of the elements (e.g., information, health 
workforce, management, infrastructure, logistics, vaccine supply, leadership, financing, and 
delivery of vaccines with complementary services) outlined in Strategic objective 4: strong 
immunization systems are an integral part of a well-functioning health system. By proposing 
a more integrated approach to service delivery and a comprehensive approach to disease 
control, as well as more effective planning of NVI that strengthens immunization and health 
systems, the Ad-hoc Working Group’s findings give an additional impetus to the GVAP. It 
is now up to countries and the international community to ensure that we are all accountable 
for giving life to these principles and for building effective evaluation mechanisms into the 
process of NVIs.
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Fig. 1. 
The WHO Health System Framework.*
*From: WHO. Everybody’s business: strengthening health systems to improve health 
outcomes – WHO’s framework for action. Geneva: World Health Organization, 2007.
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